首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1542907

全球输血诊断市场 - 2024-2031

Global Transfusion Diagnostics Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

输血诊断市场规模

全球输血诊断市场在2023年达到24.9亿美元，预计2031年将达到38.4亿美元，2024-2031年预测期间复合年增长率为5.7%。

输血诊断市场动态

由于血癌、严重伤害和事故的发生率不断上升，对这些诊断产品的需求不断增加。手术数量的增加、研发支出的增加以及新产品推出的成长预计将推动市场成长。

不断增加的新产品推出以及不断增加的严重伤害和事故案件将推动市场成长。

全球输血诊断市场主要是由医疗保健产业对诊断产品的需求所推动的，这是由于慢性疾病不断增加，包括血癌、贫血、镰状细胞性贫血、肾臟疾病和输血传染感染等严重感染。事故、创伤和痛苦手术数量的增加推动了市场的成长。例如，2022 年 8 月，QuidelOrtho Corporation 宣布为其子公司体外诊断服务提供者 Ortho Clinical 开发的 Ortho 工作站获得 AABB「符合标准」指定品质印章。该工作站是一种血液检测系统，具有二合一功能，结合了培养箱和离心机。

各种资金、新颖的技术进步以及最新创新产品的推出数量都在增加，导致对这些输血诊断的高需求。例如，2022年7月，罗氏推出了Elecsys HCV Duo免疫测定法，这是第一个允许透过单一人体样本独立检测丙型肝炎病毒抗体和抗原状态的免疫测定法。此测试可以在早期阶段检测出感染，并且可以在患者的恢復阶段或出现慢性感染症状时使用。

与输血诊断相关的高成本将阻碍市场的成长。

然而，用于输血诊断的有品质保证的试剂盒和仪器的高比例是限製成长的主要因素。由于缺乏经验丰富的专业人员，因此很难操作自动化仪器并提供准确的结果。

COVID-19 影响分析

疫情对全球金融预期、营运和危机应对策略产生了负面影响。 COVID-19 的爆发严重影响了医疗保健产业。由于新冠疫情，所有捐血活动都被取消，输血诊断市场遭受了巨大损失。由于新冠病毒的传播和输血传染，人们拒绝接受输血。但现在，市场参与者正在改变他们的长期和短期成长策略，利用研究市场并创造尖端产品来对抗这场流行病。全球正在发生各种倡议、合作和合併，促进了市场的成长。例如，2022年8月，体外诊断创新技术提供者QuidelOrtho Corp宣布加入血液与生物治疗促进协会成立的联盟“联盟”，旨在加强血液供应。

输血诊断市场区隔分析

疾病筛检领域预计在预测期内（2024-2031）将以最快的复合年增长率成长

疾病筛检领域是全球输血诊断市场中最大的市场占有者。所有捐赠的血液都经过筛检，以获取血液中不存在任何感染的证据，然后再将血液及其成分用于临床，称为疾病筛检。引入针对病毒特异性抗原和抗体的血清学检测对于检测捐赠血液中的感染非常有用，例如输血传播的传染源，如 TTI、HIV、乙型肝炎病毒和丙型肝炎病毒。最新核酸扩增技术筛检，有效降低感染风险。

由于全球血癌病例增加，疾病筛检在市场上占据主导地位。根据世界卫生组织统计，到2022年，全球每年约有124万例血癌病例。患有血液相关疾病的人数不断增加、监管部门的批准以及技术进步或研究/临床试验的不断发展推动了市场的成长。例如，2022 年 6 月，血浆衍生疗法和创新诊断解决方案开发商 Grifols 宣布 Procleix Plasmodium Assay 获得 CE 标誌，这是第一个专为疟疾相关患者捐血者设计的自动核酸检测系统。

输血诊断市场地理份额

北美地区占据全球输血诊断市场最大的市场份额。

北美在全球输血诊断市场中占据主导地位，这主要是由于全球环境不断变化、医疗基础设施完善以及对研发活动的投资增加，导致血癌、贫血、血友病、肾臟病等慢性疾病的患病率不断上升。此外，其广泛的患者群体也促进了其份额的成长。根据世界卫生组织预测，到2022年，全球将有超过200万人患有贫血症，影响全球约25%的人口。

此外，产品发布数量的增加也是市场成长的原因。其他因素，例如国内生产毛额在医疗保健方面的高支出，刺激了市场的成长。该地区正在发生许多关键的发展、技术进步、合作和协议。例如，2022 年 9 月，血浆药品製造商 Grifols 宣布与加拿大国家血液管理局 Canadian Blood Services 达成协议，以扩大其在基本血浆蛋白疗法和免疫球蛋白药物方面的自给自足。

输血诊断市场公司及竞争格局

输血诊断市场与本地和全球公司的竞争非常激烈。 Ortho Clinical Diagnostics、Beckman Coulter、Quotient Limited、Abbott Laboratories、Diagast、Becton、Dickinson & Company、Immucor Inc.、Grifols SA、Bio-Rad Laboratories、F. Hoffmann-La Roche Ltd. 等。主要参与者正在采取各种成长策略，例如产品发布、併购、合作伙伴关係和协作，为市场的成长做出贡献。例如，2022年5月，Quidel Corporation宣布交易完成，与Ortho Clinical Diagnostics Holdings合併，成立体外诊断产品及服务供应商公司QuidelOrtho Corporation。

骨科临床诊断：

概述：

Ortho Clinical Diagnostics 是一家提供血型体外诊断设备的公司。它生产自动化和半自动化测试产品以及测试菜单产品。成立于1939年，总部位于美国新泽西州。

产品组合：

Ortho Vision平台：该平台由测试血液相容性的分析仪组成，以确保患者在输血期间接受正确的血型。正交视觉产品专为大容量实验室而设计，可进行复杂的免疫血液学测试，包括连续稀释、识别特定细胞抗体和反射测试。

主要进展：2021 年 9 月，体外诊断公司 Ortho Clinical Diagnostics 宣布推出立即旋转交叉配血 (ISXM)，该系统将有助于确定受血者和捐赠者之间输血过程中的不相容性。此血清学检验可确定受者血浆和供者红血球之间 ABO 血型的不相容性。

全球输血诊断市场报告将提供约 40 多个市场资料表、45 多个图表和 200（大约）页数。

The global market for transfusion diagnostics is primarily driven by the healthcare industry's demand for diagnostic products due to increasing chronic illnesses, including blood cancer, anemia, sickle cell anemia, kidney disease and serious infection such as transfusion-transmitted infections. The rising number of accidents, trauma and painful surgeries drive the market's growth. For instance, in Aug 2022, QuidelOrtho Corporation announced receiving AABB "standards compliant" designation quality seal for an Ortho workstation developed by its subsidiary, Ortho Clinical, in vitro diagnostic services provider. This workstation is a blood testing system that has a 2-in-1 feature as it combines an incubator and a centrifuge.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these transfusion diagnostics. For instance, in July 2022, Roche launched Elecsys HCV Duo immunoassay, the first immunoassay that permits independent detection of hepatitis C virus antibodies and antigen status by a single human sample. This test can detect the infection at an early stage and can be used during the patient's recovery phase or when showing chronic infection symptoms.

The high costs associated with transfusion diagnostics will hamper the market's growth.

However, high rates of quality-assured kits and instruments for transfusion diagnostics are the major factor restraining the growth. The unavailability of experienced professionals makes it difficult to handle the automated instruments and provide accurate results.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transfusion diagnostics market has experienced huge losses due to COVID, as all the blood drives were canceled. People refused to get transfusions because of the spread of COVID and transfusion-transmitted infections. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, QuidelOrtho Corp, in vitro diagnostic innovative technology provider, announced joining the Alliance, a coalition established by the Association for Advancement of Blood and Biotherapies to strengthen the blood supply.

Transfusion Diagnostics Market Segmentation Analysis

The disease screening segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)

The disease screening segment is the highest market holder in the global transfusion diagnostics market. All the blood donated is screened to get evidence of the absence of any infection in the blood before releasing the blood and its components for clinical use, which is known as disease screening. Introducing serological assays that target virus-specific antigens and antibodies is very useful for detecting infection in donated blood, such as transfusion-transmitted infectious agents like TTIs, HIV, hepatitis B virus and hepatitis C virus. The latest nucleic acid amplification technology screening effectively minimizes the risk of infection.

Disease screening dominates the market due to increased blood cancer cases globally. According to the World Health Organization, in 2022, approximately 1.24 million blood cancer cases occur globally annually. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For Instance, in Jun 2022, Grifols, plasma-derived therapy and innovative diagnostic solutions developer, announced receiving the CE mark for Procleix Plasmodium Assay, 1st automatic nucleic acid test system specially designed for blood donors for patients related to malaria.

Transfusion Diagnostics Market Geographical Share

North America region holds the largest market share of the global transfusion diagnostics market.

North America dominates the global transfusion diagnostics market, primarily attributed to the rising prevalence of chronic ailments such as blood cancer, anemia, hemophilia, kidney disease and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the World Health Organization, in 2022, more than 2 million people will suffer from anemia globally, affecting around 25% of the world's population.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Sep 2022, Grifols, a plasma medicine manufacturer, announced its agreement with Canada's national blood authority, Canadian Blood Services, to expand its self-sufficiency in essential plasma protein therapies and immunoglobulin medicines.

Transfusion Diagnostics Market Companies and Competitive Landscape

The transfusion diagnostics market is highly competitive with local and global companies' presence. Ortho Clinical Diagnostics, Beckman Coulter, Quotient Limited, Abbott Laboratories, Diagast, Becton, Dickinson & Company, Immucor Inc., Grifols S.A., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, Quidel Corporation announced transaction completion to combine with Ortho Clinical Diagnostics Holdings to form QuidelOrtho Corporation, in vitro diagnostic products and services provider company.

Ortho Clinical Diagnostics:

Overview:

Ortho Clinical Diagnostics is a company that provides in vitro diagnostic equipment for blood typing. It produces automated and semiautomated testing products and testing menu products. It was established in 1939 and is headquartered in New Jersey, United States.

Product Portfolio:

Ortho Vision Platform: This platform comprises analyzers that test the compatibility of blood to make sure that patients receive the correct blood type during transfusion. Ortho vision products are designed for high-volume labs, allowing complex immunohematology testing, including serial dilutions, identifying particular cell antibodies and reflex tests.

Key Development: In Sep 2021, Ortho Clinical Diagnostics, an in vitro diagnostic company, announced the launch of Immediate Spin Crossmatch (ISXM) that will provide aid in determining the incompatibility during blood transfusion between the recipients and donors. This serological test determines the incompatibility of ABO blood type between the recipient plasma and donor RBCs.

The global transfusion diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

1. Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The rising novel product launches
  - 4.1.1.2. Increasing demand for diagnostic transfusion products
- 4.1.2. Restraints:
  - 4.1.2.1. High cost associated with diagnostic transfusion instruments
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces
5.2. Unmet Needs
5.3. Supply chain Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Instruments & Kits*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Reagents
7.4. Others

8. By Transfusion Types

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 8.1.2. Market Attractiveness Index, By Transfusion Types
8.2. Red Blood Cell Transfusion *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Platelet Transfusion
8.4. Plasma Transfusion
8.5. Whole Blood Transfusion

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Disease Screening *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Blood Typing
9.4. Others

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Blood Banks*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Hospitals
10.4. Laboratories
10.5. Plasma Fractionation Facilities
10.6. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. The U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. The U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
- 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of Key Companies to Watch

13. Company Profiles

13.1. Ortho Clinical Diagnostics
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Key Highlights
- 13.1.4. Financial Overview
13.2. Beckman Coulter
13.3. Quotient Limited
13.4. Abbott Laboratories
13.5. Diagast
13.6. Becton, Dickinson & Company
13.7. Immucor Inc.
13.8. Grifols S.A.
13.9. Bio-Rad Laboratories
13.10. F. Hoffmann-La Roche Ltd.(*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

14.1. Appendix
14.2. About Us and Services
14.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球输血诊断市场 - 2024-2031